Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/comparison-of-quantitative-methods-on-fdg-pet-ct-for-treatment-QZA2x3J6yw
References (27)
-
M. Rahim, Sung Kim, Hyeongryul So, Hyung Kim, G. Cheon, Eun Lee, K. Kang, D. Lee (2014)
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear OncologyNuclear Medicine and Molecular Imaging, 48
-
K Pinker, C Riedl, L Ong, M Jochelson, GA Ulaner, H McArthur (2016)
Impact of the number of lesions analyzed in metastatic breast cancer on response assessment by 18F-FDG PET/CT using PERCISTJ Nucl Med
-
L. Geus-Oei, D. Vriens, H. Laarhoven, W. Graaf, W. Oyen (2009)
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic ReviewJournal of Nuclear Medicine, 50
-
K. Pinker, C. Riedl, Leonard Ong, M. Jochelson, G. Ulaner, H. McArthur, M. Dickler, M. Gönen, W. Weber (2016)
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCISTThe Journal of Nuclear Medicine, 57
-
Kyoungjune Pak, G. Cheon, Hyun-Yeol Nam, Seong-Jang Kim, K. Kang, June-Key Chung, E. Kim, D. Lee (2014)
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-AnalysisThe Journal of Nuclear Medicine, 55
-
T Berghmans, M Dusart, M Paesmans, C Hossein-Foucher, I Buvat, C Castaigne (2008)
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging ProjectJ Thorac Oncol, 3
-
R. Wahl, H. Jacene, Y. Kasamon, M. Lodge (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 50
-
H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra, A. Lammertsma, J. Pruim, P. Price (1999)
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.European journal of cancer, 35 13
-
Ercan Kurtipek, M. Çaycı, Nuri Düzgün, H. Esme, Y. Terzi, S. Bakdık, M. Aygün, Yaşar Unlü, Cengiz Burni̇k, T. Bekçi (2015)
18F-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non–Small Cell Lung CancerClinical Nuclear Medicine, 40
-
M. Findlay, H. Young, D. Cunningham, A. Iveson, B. Cronin, T. Hickish, B. Pratt, J. Husband, M. Flower, R. Ott (1996)
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
-
A. Grothey, E. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R. Goldberg, D. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 381
-
K. Skougaard, D. Nielsen, B. Jensen, H. Hendel (2013)
Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and CetuximabThe Journal of Nuclear Medicine, 54
-
Y. Lim, Sae-Won Han, J. Yoon, J. Lee, Jung Lee, J. Paeng, J. Won, G. Kang, Seung-Yong Jeong, K. Park, Kyung-Hun Lee, J. Kim, Tae-You Kim (2015)
Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal CancerPLoS ONE, 10
-
Chieh Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J. Talbot, A. Rahmouni, M. Meignan (2007)
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual AnalysisJournal of Nuclear Medicine, 48
-
R. Minamimoto, Amir Barkhodari, L. Harshman, S. Srinivas, A. Quon (2016)
Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell CarcinomaPLoS ONE, 11
-
L. Geus-Oei, H. Laarhoven, E. Visser, Rick Hermsen, B. Hoorn, Yvonne Kamm, Paul Krabbe, F. Corstens, C.J.A. Punt, W. Oyen (2008)
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 19 2
-
A. Wong, Joline Lim, A. Sinha, A. Gopinathan, R. Lim, C. Tan, T. Soh, S. Venkatesh, Christina Titin, N. Sapari, Soo-Chin Lee, W. Yong, D. Tan, B. Pang, Ting-ting Wang, Y. Zee, R. Soong, Z. Trnkova, C. Lathia, J. Thiery, S. Wilhelm, M. Jeffers, B. Goh (2015)
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibJournal of Translational Medicine, 13
-
H. Bender, N. Bangard, Nina Metten, Michael Bangard, J. Mezger, A. Schomburg, H. Biersack (1999)
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.Hybridoma, 18 1
-
M. Yanagawa, M. Tatsumi, H. Miyata, E. Morii, N. Tomiyama, T. Watabe, K. Isohashi, H. Kato, E. Shimosegawa, M. Yamasaki, M. Mori, Y. Doki, J. Hatazawa (2012)
Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid TumorsThe Journal of Nuclear Medicine, 53
-
M. Benz, J. Czernin, M. Allen-Auerbach, W. Tap, S. Dry, D. Elashoff, Kira Chow, V. Evilevitch, J. Eckardt, M. Phelps, W. Weber, F. Eilber (2009)
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue SarcomasClinical Cancer Research, 15
-
H. Chalian, H. Töre, J. Horowitz, R. Salem, F. Miller, V. Yaghmai (2011)
Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.Radiographics : a review publication of the Radiological Society of North America, Inc, 31 7
-
A. Dimitrakopoulou-Strauss, L. Strauss, C. Burger, A. Rühl, G. Irngartinger, W. Stremmel, J. Rudi (2004)
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 45 9
-
A. Dimitrakopoulou-Strauss, L. Strauss, J. Rudi (2003)
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology, 47 1
-
M. Hatt, R. Stiphout, A. Pogam, G. Lammering, D. Visvikis, P. Lambin (2013)
Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PETActa Oncologica, 52
-
S. Eschmann, Godehard Friedel, Frank Paulsen, Matthias Reimold, T. Hehr, W. Budach, Helmut Dittmann, Heinz-Jakob Langen, Roland Bares (2007)
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.Lung cancer, 55 2
-
B. Byun, Chang-Bae Kong, Jihyun Park, Y. Seo, I. Lim, C. Choi, W. Cho, D. Jeon, J. Koh, Soo‐Yong Lee, S. Lim (2013)
Initial Metabolic Tumor Volume Measured by 18F-FDG PET/CT Can Predict the Outcome of Osteosarcoma of the ExtremitiesThe Journal of Nuclear Medicine, 54
-
J. Farnebo, P. Grybäck, U. Harmenberg, A. Laurell, P. Wersäll, L. Blomqvist, A. Ullén, P. Sandström (2014)
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinomaBMC Cancer, 14
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by Korean Society of Nuclear Medicine
- Subject
- Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
- ISSN
- 1869-3474
- eISSN
- 1869-3482
- DOI
- 10.1007/s13139-016-0449-2
- Publisher site
- See Article on Publisher Site
Abstract
Nucl Med Mol Imaging (2017) 51:147–153 DOI 10.1007/s13139-016-0449-2 ISSN (print) 1869-3482 ORIGINAL ARTICLE ISSN (online) 1869-3474 Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer 1 2 1 2 1 Ji-In Bang & Yoojoo Lim & Jin Chul Paeng & Sae-Won Han & Sohyun Park & 1 1 1 1 Jung Min Lee & Hyun Joo Kim & Gi Jeong Cheon & Dong Soo Lee & 1 2 1 June-Key Chung & Tae-You Kim & Keon Wook Kang Received: 1 June 2016 /Revised: 21 August 2016 /Accepted: 30 August 2016 /Published online: 13 September 2016 Korean Society of Nuclear Medicine 2016 Abstract (particularly, 30–50 % of maximum SUV) exhibited significant Purpose FDG PET is effective in treatment response evalua- differences between the two groups, and high diagnostic power tion of cancer. However, there is no standard method for quan- for the response by the RECIST criteria. TLG-based criteria, titative evaluation of FDG PET, particularly regarding cyto- which used a margin threshold of 50 % of maximum SUV, static drugs. We compared various FDG PET quantitative exhibited a high agreement with the RECIST criteria compared methods in terms of response determination. with the PERCIST
Journal
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Sep 13, 2016